After 16 long years without any truly viable treatment options for Alzheimer’s, there is some optimism on the horizon in a stunning reversal on the formerly-rejected antibody therapy, aducanumab. The newest research reveals that large quantities of the medication do, in fact, decrease cognitive decline at the beginning stages of Alzheimer’s.
According to Rebecca Edelmayer, director of scientific engagement at the Alzheimer’s Association, “It could be a game-changer for the field. It could be one of the first disease-modifying therapies approved for Alzheimer’s disease.”
Biogen, the maker of aducanumab, reports significant benefits for dementia patients in a number of areas: activities of daily living, memory, language, and orientation. Biogen introduced its intentions to pursue regulatory approval in the U.S., with a long range aim of launching the medication internationally.
With an expected request for approval by the FDA as quickly as early 2020, the drug is slated to possibly become the first treatment method to actually reduce the clinical decline of Alzheimer’s. Additionally, it should open doors to many other treatment options that impact amyloid beta plaques, connecting other trials that target the immune system, inflammation, blood vessels, and synaptic cell health. Searching for the most beneficial management of the disease is a challenging endeavor, and it is likely that a variety of these approaches will be necessary, according to Edelmayer.
The next challenge? Persuading the FDA to approve the treatment after earlier failed trials. If approved, aducanumab will first be provided to those who had signed up for earlier trials, and hopefully, soon offered to others dealing with all the challenges of Alzheimer’s as well.
For the approximate six million senior Americans battling Alzheimer’s (a number expected to more than double during the next three decades), plus the family who take care of them, these latest findings could be life-changing, as there are presently only minimally effective symptom-management medications available. As we await a treatment, the team at JFS Care is ready to assist dementia patients with highly skilled, trained, and qualified caregivers who make the most of creative, therapeutic approaches that focus on each person’s distinct strengths and ensure each individual is living to the fullest possible potential.
Families have options for home care assistance in Beverly Hills and surrounding areas that can help with Alzheimer’s care; see our full service area. To learn more about highly effective Alzheimer’s care that will help boost quality of life within the comfort of home, contact the dementia care experts at JFS Care at (213) 383-2273 and request an in-home assessment or additional information.